AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3453187 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 7006
Study 31851240 — intervention group
Group type: EXPERIMENTAL
Intervention: Hammock position
Number of subjects: 20
Study 31851240 — intervention group
Group type: COMPARATOR
Intervention: Nesting position
Number of subjects: 20
Study 29392743 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD 1% pet. (6 mg)
Number of subjects: 17
Study 29392743 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD 0.3% pet. (20 mg)
Number of subjects: 17
Study 29392743 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses (PPD 1% and PPD 0.3%)
Number of subjects: 17
Study 26866638 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication (MED; n = 50)
Number of subjects: 149
Study 26866638 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive therapy (SET; n = 49)
Number of subjects: 149
Study 26866638 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill (PBO; n = 50)
Number of subjects: 149
Study 26866638 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (MED, SET, PBO)
Number of subjects: 149
Study 26866638 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive therapy (SET)
Number of subjects: 149
Study 26866638 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication (MED)
Number of subjects: 149
Study 25448672 — intervention group
Group type: EXPERIMENTAL
Intervention: IBPB associated with Intravenous‐inhalation combined anesthesia (group NB)
Number of subjects: 100
Study 25448672 — intervention group
Group type: COMPARATOR
Intervention: Intravenous‐inhalation combined anesthesia (group CI)
Number of subjects: 100
Study 21789517 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted vaginal hysterectomy (LAVH)
Number of subjects: 20
Study 21789517 — intervention group
Group type: COMPARATOR
Intervention: Non-descent vaginal hysterectomy (NDVH)
Number of subjects: 20
Study 20173709 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic mouth-rinse containing chlorhexidine and cetylpyridinium chloride
Number of subjects: 36
Study 20173709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18161933 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial splenic embolization (PSE) combined with transcatheter hepatic arterial chemoembolization (TACE)
Number of subjects: 50
Study 18161933 — intervention group
Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 50
Study 16451305 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical agents incorporated in dentifrice or mouth rinse formulations
Number of subjects: 0
Study 16451305 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12847372 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 percent glyceryl trinitrate ointment
Number of subjects: 110
Study 12847372 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 110
Study 11938776 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (10mg to 40mg once daily)
Number of subjects: 80
Study 11938776 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50mg to 100mg once daily)
Number of subjects: 80
Study 11938776 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (Group A)
Number of subjects: 80
Study 11938776 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (Group B)
Number of subjects: 80
Study 11938776 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Carvedilol and Atenolol)
Number of subjects: 80
Study 9031394 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen-I: artemether (300 mg) plus pyrimethamine (100 mg) on the first day, then placebo on the two consecutive days
Number of subjects: 60
Study 9031394 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen-II: artemether (300 mg) plus pyrimethamine (100 mg) on the first day, then artemether (150 mg) plus pyrimethamine (50 mg) on the second day, and placebo on the third day
Number of subjects: 60
Study 9031394 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen-III: artemether (300 mg) plus pyrimethamine (100 mg) on the first day, then artemether (150 mg) plus pyrimethamine (50 mg) on the second and third days
Number of subjects: 60
Study 1285244 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary trypsin inhibitory activity
Number of subjects: 690
Study 1285244 — intervention group
Group type: COMPARATOR
Intervention: C-Reactive protein
Number of subjects: 690
Study 6347753 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (50 mg four times a day)
Number of subjects: 37
Study 6347753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 31254226 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-bonded polysulfone membrane hemodialyzer (ViE™‐21)
Number of subjects: 17
Study 31254226 — intervention group
Group type: COMPARATOR
Intervention: Conventional high‐flux hemodialyzers
Number of subjects: 17
Study 30107480 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle education - dyad group (both women and husbands)
Number of subjects: 189
Study 30107480 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle education - women only group
Number of subjects: 189
Study 30107480 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 189
Study 27075914 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitrate (NaNO3)
Number of subjects: 18
Study 27075914 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated beetroot juice
Number of subjects: 18
Study 27075914 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocket salad beverage
Number of subjects: 18
Study 27075914 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach beverage
Number of subjects: 18
Study 24532525 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2 μg/(kg·h)⁻¹)
Number of subjects: 96
Study 24532525 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 96
Study 23422630 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% triphala mouthwash, 15 ml twice a day
Number of subjects: 60
Study 23422630 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine mouthwash, 15 ml twice a day
Number of subjects: 60
Study 23422630 — intervention group
Group type: COMPARATOR
Intervention: Plain water rinse, twice a day
Number of subjects: 60
Study 20347681 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent mechanical compression (IMC) applied at 65 mm Hg for two hours/day for three months.
Number of subjects: 30
Study 20347681 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT) alone.
Number of subjects: 30
Study 17908626 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-node radiotherapy
Number of subjects: 0
Study 17908626 — intervention group
Group type: EXPERIMENTAL
Intervention: Early positron emission tomography scan with fluorodeoxyglucose
Number of subjects: 0
Study 16274477 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ibuprofen
Number of subjects: 283
Study 16274477 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen
Number of subjects: 283
Study 12358658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular clonidine (2 microg x kg(‐1))
Number of subjects: 39
Study 12358658 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 39
Study 10199426 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid defibrillation program optimization (including defibrillation by firefighters, base paging, tiered response agreements, continuous quality improvement, and standard dispatch policies)
Number of subjects: 6331
Study 7539270 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 47
Study 7539270 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 47
Study 1688913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 40 (500 ml per session) during 3 weeks
Number of subjects: 20
Study 1688913 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatments for 3 weeks
Number of subjects: 20
Study 7387900 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 40 mg daily with gradual reduction over a period of 4 weeks
Number of subjects: 40
Study 7387900 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine 100 mg four times daily
Number of subjects: 40
Study 30529393 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 153
Study 30529393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 30529393 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 153
Study 29061430 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning through Play Plus program (LTP Plus)
Number of subjects: 247
Study 29061430 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 247
Study 26303700 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0
Study 26303700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24415640 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil plus rituximab (CLB-R)
Number of subjects: 85
Study 24415640 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance (375 mg/m2, 12 doses)
Number of subjects: 85
Study 24415640 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 85
Study 24415640 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil (8 mg/m2/day, days 1-7) and Rituximab (375 mg/m2 on day 1 of cycle 3, 500 mg/m2 for cycles 4-8)
Number of subjects: 85
Study 22829268 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day
Number of subjects: 140
Study 22829268 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/day
Number of subjects: 140
Study 22829268 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 3 mg/day
Number of subjects: 140
Study 22829268 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day and 10 mg/day
Number of subjects: 140
Study 22829268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 19193706 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt containing Bifidobacterium animalis subsp. lactis DN-173010 (2 x 10(8) CFU/g), 200 g once daily for 2 weeks
Number of subjects: 24
Study 19193706 — intervention group
Group type: COMPARATOR
Intervention: Control yogurt without viable bacteria, 200 g once daily for 2 weeks
Number of subjects: 24
Study 17185016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen 1mg/kg i.v. at skin closure, and at 8 and 16 hours after surgery
Number of subjects: 31
Study 17185016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen
Number of subjects: 31
Study 17185016 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 31
Study 14975544 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg o.d. added to statin therapy (fluvastatin 40 mg)
Number of subjects: 283
Study 14975544 — intervention group
Group type: COMPARATOR
Intervention: Control group (statin therapy only)
Number of subjects: 283
Study 14975544 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg o.d. added to statin therapy
Number of subjects: 283
Study 11223689 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiandrogen withdrawal
Number of subjects: 44
Study 9555595 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 8 mg once daily
Number of subjects: 211
Study 9555595 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 4 mg twice daily
Number of subjects: 211
Study 9555595 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 211
Study 8200551 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline alone (3-10 ml of 1:100,000 adrenaline)
Number of subjects: 107
Study 8200551 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline plus ethanolamine oleate (5%)
Number of subjects: 107
Study 3312133 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50 mg elemental zinc/day)
Number of subjects: 0
Study 3312133 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29371262 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month structured lifestyle programme
Number of subjects: 564
Study 29371262 — intervention group
Group type: COMPARATOR
Intervention: Infertility care as usual
Number of subjects: 564
Study 28557676 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention based on the Valencia Model of Waking Hypnosis combined with Cognitive‐Behavioral Therapy
Number of subjects: 0
Study 28557676 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 0
Study 26084292 — intervention group
Group type: EXPERIMENTAL
Intervention: PCH (trastuzumab and paclitaxel weekly combined with carboplatin weekly)
Number of subjects: 100
Study 26084292 — intervention group
Group type: COMPARATOR
Intervention: PEH (epirubicin every 3 weeks combined with trastuzumab and paclitaxel)
Number of subjects: 100
Study 24011142 — intervention group
Group type: COMPARATOR
Intervention: Motivational interviewing tailored lifestyle intervention (MINT)
Number of subjects: 480
Study 24011142 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted patient navigation (PN) intervention
Number of subjects: 480
Study 21943032 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (DCT) 20 mg/m2/week and continuous fluorouracil (5-FU) 200 mg/m2/day plus concurrent radiotherapy
Number of subjects: 40
Study 21943032 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (DCT) 20 mg/m2/week and cisplatin (CDDP) 20 mg/m2 plus concurrent radiotherapy
Number of subjects: 40
Study 19047492 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led hospice collaborative; specific details on dosage and duration not available.
Number of subjects: 0
Study 19047492 — intervention group
Group type: COMPARATOR
Intervention: Classroom instruction; specific details on dosage and duration not available.
Number of subjects: 0
Study 19047492 — intervention group
Group type: COMPARATOR
Intervention: Combination of classroom and hospice experiences; specific details on dosage and duration not available.
Number of subjects: 0
Study 14712904 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention carried out by outreach visitors
Number of subjects: 62
Study 14712904 — intervention group
Group type: EXPERIMENTAL
Intervention: Costs of the intervention
Number of subjects: 62
Study 10225493 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-session family intervention
Number of subjects: 428
Study 10225493 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control condition
Number of subjects: 428
Study 7600600 — intervention group
Group type: EXPERIMENTAL
Intervention: Denmark II lyophilized vaccines
Number of subjects: 0
Study 2223928 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP), 80 mg/day
Number of subjects: 6
Study 2223928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 352417 — intervention group
Group type: EXPERIMENTAL
Intervention: eserine amine oxide
Number of subjects: 14
Study 352417 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 352417 — intervention group
Group type: EXPERIMENTAL
Intervention: pentagastrin
Number of subjects: 14
Study 352417 — intervention group
Group type: EXPERIMENTAL
Intervention: histamine
Number of subjects: 14
Study 30941424 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg intravenously every 2 weeks
Number of subjects: 821
Study 30941424 — intervention group
Group type: COMPARATOR
Intervention: Everolimus 10 mg orally once daily
Number of subjects: 821
Study 30941424 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 821
Study 30941424 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 821
Study 28717929 — intervention group
Group type: EXPERIMENTAL
Intervention: CAS‐based pharmacist‐physician intervention
Number of subjects: 231
Study 28717929 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 231
Study 26536017 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport
Number of subjects: 34
Study 26536017 — intervention group
Group type: COMPARATOR
Intervention: Prosigne
Number of subjects: 34
Study 23618879 — intervention group
Group type: EXPERIMENTAL
Intervention: Agenda-setting form distributed to patients (77 patients)
Number of subjects: 113
Study 23618879 — intervention group
Group type: EXPERIMENTAL
Intervention: Agenda-setting form (intervention group)
Number of subjects: 113
Study 23618879 — intervention group
Group type: COMPARATOR
Intervention: Control group (36 patients)
Number of subjects: 113
Study 21949699 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV delivered via autologous ex vivo transfected dendritic cells (DC)
Number of subjects: 15
Study 21949699 — intervention group
Group type: COMPARATOR
Intervention: ALVAC-HIV delivered intramuscularly (i.m.)
Number of subjects: 15
Study 21949699 — intervention group
Group type: COMPARATOR
Intervention: ALVAC-HIV delivered intradermally (i.d.)
Number of subjects: 15
Study 21949699 — intervention group
Group type: COMPARATOR
Intervention: ALVAC-HIV delivered subcutaneously (s.q.)
Number of subjects: 15
Study 19526744 — intervention group
Group type: EXPERIMENTAL
Intervention: Nidotherapy enhanced assertive treatment (up to 12 sessions)
Number of subjects: 52
Study 19526744 — intervention group
Group type: COMPARATOR
Intervention: Continued assertive outreach care
Number of subjects: 52
Study 17341178 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial treatment
Number of subjects: 0
Study 17341178 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment therapy
Number of subjects: 0
Study 17341178 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH Chronic Prostatitis Symptom Index
Number of subjects: 0
Study 17341178 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-glass test
Number of subjects: 0
Study 17341178 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-glass test
Number of subjects: 0
Study 16134605 — intervention group
Group type: EXPERIMENTAL
Intervention: S (+) ‐ismer of ibuprofen suppository (one suppository per day for 3 days)
Number of subjects: 163
Study 16134605 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen suppository (one suppository per day for 3 days)
Number of subjects: 163
Study 11842836 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg/night
Number of subjects: 10
Study 11842836 — intervention group
Group type: COMPARATOR
Intervention: Placebo 25 mg/night
Number of subjects: 10
Study 9990417 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel applied immediately after washing
Number of subjects: 25
Study 9990417 — intervention group
Group type: COMPARATOR
Intervention: Adapalene 0.1% gel applied 20-30 min after washing
Number of subjects: 25
Study 7800211 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium acetate
Number of subjects: 31
Study 7800211 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 31
Study 3378661 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprozin 1200 mg/day
Number of subjects: 40
Study 3378661 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium 100 mg/day
Number of subjects: 40
Study 31169393 — intervention group
Group type: EXPERIMENTAL
Intervention: family CBT
Number of subjects: 128
Study 31169393 — intervention group
Group type: EXPERIMENTAL
Intervention: child CBT
Number of subjects: 128
Study 26414279 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (Keep your brain fit!)
Number of subjects: 376
Study 26414279 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 376
Study 25505221 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy training (n = 15, 10 sessions as adjunct to usual inpatient rehabilitation)
Number of subjects: 30
Study 25505221 — intervention group
Group type: COMPARATOR
Intervention: Reflective listening (n = 15, same dose)
Number of subjects: 30
Study 25505221 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy training
Number of subjects: 30
Study 23644179 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg)
Number of subjects: 1039
Study 23644179 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (80 mg)
Number of subjects: 1039
Study 21326270 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberry yogurt-based drink supplemented with B. lactis BB-12
Number of subjects: 172
Study 21326270 — intervention group
Group type: COMPARATOR
Intervention: Placebo yogurt drink without B. lactis BB-12
Number of subjects: 172
Study 19039612 — intervention group
Group type: EXPERIMENTAL
Intervention: Single task (change detection task)
Number of subjects: 30
Study 19039612 — intervention group
Group type: COMPARATOR
Intervention: Dual task (change detection and PASOT)
Number of subjects: 30
Study 17218378 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (Group G)
Number of subjects: 0
Study 17218378 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with epidural anaesthesia (Group E)
Number of subjects: 0
Study 15008994 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human TSH (rhTSH) 0.45 mg pretreatment before RAI treatment
Number of subjects: 34
Study 15008994 — intervention group
Group type: COMPARATOR
Intervention: Radioactive iodine (RAI) treatment
Number of subjects: 34
Study 11319712 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable oil-based stanols (2.6 g sitostanol plus 1.2 g campestanol daily)
Number of subjects: 112
Study 11319712 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood-based stanols (3.7 g sitostanol plus 0.3 g campestanol daily)
Number of subjects: 112
Study 11319712 — intervention group
Group type: COMPARATOR
Intervention: Control group (LEAR-based margarine and shortening)
Number of subjects: 112
Study 9773392 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir
Number of subjects: 0
Study 7846220 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological blockades during psychological stress tasks (speech stress, mental arithmetic, reaction-time task)
Number of subjects: 0